Novel Biologic for Moderate-to-Severe Atopic Dermatitis

Evaluating the safety and efficacy of a novel biologic therapy in adults with moderate-to-severe atopic dermatitis who have not responded to topical treatments.

Duration

28 weeks

Visits

12 visits

Compensation

Up to $1,200

Study Overview

This Phase II randomized, double-blind, placebo-controlled study investigates a novel biologic targeting the IL-4/IL-13 pathway in adults aged 18–65 with moderate-to-severe atopic dermatitis (IGA score ≥3). Participants will receive subcutaneous injections every 2 weeks over 16 weeks, with a 12-week follow-up period. The primary endpoint is EASI-75 response at Week 16.

Eligibility Criteria

You May Qualify If:

Adults aged 18–65
Diagnosed with moderate-to-severe atopic dermatitis (IGA score ≥3)
Inadequate response to topical corticosteroids or calcineurin inhibitors
Stable disease for at least 3 months

You May Not Qualify If:

Active skin infections at screening
Use of systemic immunosuppressants within 4 weeks
History of malignancy within 5 years
Pregnant or breastfeeding

Study Locations

Tampa Main OfficeClearwater Office

Apply for This Study

Complete this brief form and our team will contact you within 1 business day.

Questions? Call us directly:

(813) 815-7327

Back to All Studies